Background: Cirrhosis often remains silent until decompensation, after which survival deteriorates sharply. Contemporary, transition-aware estimates are limited, especially in Asian-predominant cohorts. We analyzed trajectories from compensated advanced chronic liver disease (cACLD) through sequential decompensations t...
E. Tan, N. S. Tang, N. Syn et al.· Hepatology Communications· 0 citations
ABSTRACT Metabolic dysfunction‐associated steatohepatitis (MASH) is driven by nutrient stress through incompletely defined epigenetic mechanisms. This study demonstrates that lipid stress activates the hexosamine biosynthesis pathway (HBP), elevating O‐linked β‐N‐acetylglucosamine (O‐GlcNAc) modification of the N6‐meth...
Jia-Xin Yin, Yan-Lai Zhang, Qun Liu et al.· Advancement of science· 0 citations
BACKGROUND
Programmed cell death factor 4 (PDCD4) has been implicated in various metabolic disorders. However, its role and underlying mechanisms in metabolic dysfunction-associated steatotic liver disease (MASLD) have not been fully elucidated.
PURPOSE
This study aimed to define the role of PDCD4 in hepatic steatosi...
Xiao-Na Cheng, Kai-Kai Lu, Lu-Yun Yang et al.· Phytomedicine· 0 citations
A higher CKM stage is associated with an increased long-term risk of MACEs and LREs across the SLD spectrum, and obesity and hypertension are the primary contributors to both outcomes, and diabetes additionally contributes to LREs.
Qiong-Yue Fan, Li-You Lian, Tian-Yi Xia et al.· i Medicina· 0 citations
This study identifies KIF13B as a novel regulator of hepatic lipid homeostasis in ALD via the KIF13B-KPNA2-PPARα axis, enhancing KPNA2 mediated nuclear import, particularly in combination with PPARα activation, represents a promising therapeutic strategy for ALD.
Kai-Kai Lu, Si Mei, Lian-Xing Zhang et al.· Gut· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.